SCHEDULE 13G/A: Frank W. Cawood Discloses 8.4% Stake in Barinthus Biotherapeutics Plc

Frank W. Cawood has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Barinthus Biotherapeutics Plc's American Depositary Shares as of December 31, 2024.

Summary

• Frank W. Cawood, a U.S. citizen, reported beneficial ownership of 3,384,513 American Depositary Shares (ADS) of Barinthus Biotherapeutics Plc.
• This ownership represents 8.4% of the company's class of securities, based on 40,228,456 ordinary shares outstanding as of October 30, 2024.
• Mr. Cawood holds sole voting and dispositive power over 2,564,136 shares, which includes 2,164,376 shares owned directly and 399,760 shares through a retirement account.
• He holds shared voting and dispositive power over 820,377 shares, comprising 151,798 shares owned by his spouse through a retirement account and 668,579 shares owned by The Cawood Foundation, Inc., a non-profit corporation with which he is affiliated.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a significant individual ownership stake can be interpreted as a vote of confidence in the company's prospects, although the filing itself is a routine disclosure.

Positives

• The disclosure of a significant beneficial ownership stake (8.4%) by an individual, Frank W. Cawood, may signal confidence in Barinthus Biotherapeutics Plc's future prospects.
• A substantial portion of the ownership (2,564,136 shares) is under Mr. Cawood's sole voting and dispositive power, indicating direct control over a significant block of shares.

Risks

• This Schedule 13G filing primarily discloses beneficial ownership and does not detail specific operational, financial, or market risks associated with Barinthus Biotherapeutics Plc.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

Barinthus Biotherapeutics Plc operates in the biotechnology sector. This filing indicates a significant individual shareholder's stake, which is a common occurrence in publicly traded companies, particularly in sectors like biotech where long-term investment by individuals or foundations can be notable.

Related Party Transactions

• The filing indicates that 668,579 shares are owned by The Cawood Foundation, Inc., a non-profit corporation of which the Reporting Person, Frank W. Cawood, is an affiliate. This constitutes a related party holding.

Stakeholder Impact

• Shareholders may view the significant ownership stake by Frank W. Cawood as a positive signal of long-term commitment and confidence in the company's value.

Key Dates

Keywords

Barinthus Biotherapeutics Plc, Frank W. Cawood, Schedule 13G, Beneficial Ownership, American Depositary Shares, ADS, Shareholder, Biotechnology, SEC Filing, Ownership Stake